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The facilitates chromatin transcription (FACT) com-
plex is involved in chromatin remodeling during
transcription, replication, and DNA repair. FACT
was previously considered to be ubiquitously ex-
pressed and not associated with any disease. How-
ever, we discovered that FACT is the target of a class
of anticancer compounds and is not expressed in
normal cells of adult mammalian tissues, except for
undifferentiated and stem-like cells. Here, we show
that FACT expression is strongly associated with
poorly differentiated aggressive cancers with low
overall survival. In addition, FACT was found to be
upregulated during in vitro transformation and to be
necessary, but not sufficient, for driving transforma-
tion. FACT also promoted survival and growth of
established tumor cells. Genome-wide mapping of
chromatin-bound FACT indicated that FACT’s role
in cancer most likely involves selective chromatin
remodeling of genes that stimulate proliferation,
inhibit cell death and differentiation, and regulate
cellular stress responses.
INTRODUCTION
The facilitates chromatin transcription (FACT) complex is a heter-
odimer of two subunits: Structure-Specific Recognition Protein 1
(SSRP1) and Suppressor of Ty (SPT16). FACT plays a role in
chromatin remodeling bymodulating nucleosome stability (Rein-
berg and Sims, 2006; Singer and Johnston, 2004) and has been
implicated in multiple processes involving chromatin, includingtranscription and DNA replication, recombination, and repair
(Saunders et al., 2003; Belotserkovskaya et al., 2003; Birch
et al., 2009; Tan et al., 2006, 2010; Zhou andWang, 2004; Kumari
et al., 2009; Heo et al., 2008; Keller et al., 2001; Ikeda et al.,
2011). Our recent discovery that FACT is the molecular target
of a class of anticancer compounds, Curaxins (CXs), provided
indication that FACT might play a role in cancer (Gasparian
et al., 2011). This possibility is supported by our findings that
FACT is expressed at higher levels in tumor cell lines than in
normal cells in vitro and that RNAi-mediated knockdown (KD)
of FACT expression leads to reduced growth and survival of
tumor cells (Gasparian et al., 2011). In addition, FACT expression
was found to be elevated during the development of mammary
carcinomas in transgenic mice expressing the Her2/neu proto-
oncogene (Koman et al., 2012). FACT’s pattern of expression
in normal (nontumor) cells is also consistent with a possible
role in tumorigenesis. Although FACT was previously considered
a ubiquitously expressed housekeeping factor (reviewed in
Singer and Johnston, 2004), we did not detect SSRP1 or
SPT16 expression in normal organs of adult humans or mice,
with the exception of some cell types in hematological and repro-
ductive organs and intestinal crypts (Garcia et al., 2011). Analysis
of publicly available gene expression data from multiple studies
revealed that FACT is expressed at high levels in undifferentiated
stem and progenitor cells in different organs and that its expres-
sion decreases upon differentiation (Garcia et al., 2011).
Herein, we confirmed the association between FACT and can-
cer by showing that FACT expression increases during in vitro
transformation of normal cells and is functionally required for
transformation as well as tumor cell survival and growth.
We showed that FACT is frequently expressed in different
types of tumors and established a statistically significant asso-
ciation between the frequency and level of SSRP1 and tumor
aggressiveness. To address the mechanism(s) by which FACTCell Reports 4, 159–173, July 11, 2013 ª2013 The Authors 159
Figure 1. FACT Subunit Levels Are Elevated
in the Process of In Vitro Transformation
(A–C) HMECs were transformed using genetic
(gray arrow) or chemical (white arrow) manipula-
tions. Primary (184), immortal (184Dp16sMY,
184B5), and fully transformed (184FMY2, 184AA3)
cells were assessed by (A) immunofluorescent
staining with antibodies to SSRP1 (scale bars,
100 mM); (B) western blotting with the indicated
antibodies; and (C) quantitative reverse-tran-
scription PCR analysis of total RNA with primers
specific to SSRP1, or SPT16 or 18S rRNA (loading
control). Data in (C) were normalized based on the
level of 18S rRNA and are shown relative to the
level of the corresponding transcripts in 184 cells
(set at 1.0). Bars indicate the mean of three repli-
cates + SD. *p < 0.05 for comparison to 184 cells.
See also Figure S1.facilitates tumor growth, we assessed genome-wide distribution
of FACT binding to chromatin in tumor cells. This identified a
subset of genes that are likely dependent upon FACT for expres-
sion and that have activities associated with malignant and
stem-like properties of tumor cells and cellular stress responses.
RESULTS
FACT Is Elevated during In Vitro Transformation
To test the hypothesis that FACT plays a role in tumorigenesis,
we compared SSRP1 and SPT16 protein levels in cultured cells
of mesenchymal or epithelial origin representing different stages
of (in vitro) transformation: finite lifespan, immortalized, or trans-
formed. There was essentially no change in FACT levels between
normal human fibroblasts and fibroblasts immortalized with
human telomerase or between mouse primary fibroblasts from
p53 wild-type (finite) or knockout (immortalized) animals (Fig-
ure S1A). However, when we transformed immortalized fibro-
blasts of either human or mouse origin with activated H-RasV12
oncogene, we observed a dramatic increase in FACT levels (Fig-
ures S1B and S1C). Importantly, the fibroblasts (finite lifespan,
immortalized, or transformed) did not have significantly different
proliferation rates; therefore, FACT upregulation was not a
reflection of increased cell proliferation.
To model epithelial cell transformation, we used previously
described human mammary epithelial cell (HMEC) strains from160 Cell Reports 4, 159–173, July 11, 2013 ª2013 The Authorsbreast reduction specimens (Garbe
et al., 2009) and isogenic immortalized
and transformed lines derived from
these cells via exposure to the chem-
ical carcinogen benzo(a)pyrene (Stamp-
fer and Bartley, 1985) or expression of
shRNA against CDKN2A (p16) and/or
the cDNA of proto-oncogene c-MYC
(Brenner et al., 1998), respectively (Fig-
ure 1). The parental (normal) HMEC
strains (184) showed almost no nuclear
SSRP1 staining, whereas transformed
derivatives capable of anchorage-inde-pendent growth (AIG) (184FMY2 and 184AA3) were strongly
SSRP1 positive (Figure 1A). Immortalized lines not capable of
AIG displayed weak but detectable SSRP1 staining. Increased
SSRP1 and SPT16 expression in successive stages of in vitro
transformation was confirmed by both western blotting (Fig-
ure 1B) and quantitative reverse-transcription PCR (Figure 1C).
Analysis of PCNA protein expression showed that these differ-
ences were not due to differences in proliferation (Figure 1B).
FACT Expression Is Required for Transformation and
for Tumor Cell Survival and Growth
To determine the functional importance of FACT elevation during
transformation, we evaluated how changes in FACT levels
affected the efficiency of H-RasV12-induced transformation of
fibroblasts and epithelial cells. We transduced p53/ mouse
embryonic fibroblast (MEF) or MCF10A (immortalized nontrans-
formed HMEC) with lentiviral H-RasV12 together with either
expression constructs for both FACT subunits or shRNAs target-
ing them. In both cell types, the efficiency of transformation was
increased by enforced FACT expression and decreased by
FACT KD. However, there were some cell-type-specific differ-
ences. Although MEFs proliferated equally well in 2D culture
with or without elevated FACT, growth of epithelial MCF10A cells
was induced by FACT overexpression (Figure 2A, compare
‘‘Empty vectors’’ with ‘‘SSRP1+SPT16’’ panels). Moreover,
transduction of MCF10A cells with H-Ras V12 led to the massive
appearance of enlarged flat vacuolated senescent-like cells and
a minor population of small, growing, transformed-looking cells
that became the majority after replating (Figure 2A, ‘‘H-RasV12’’
plus ‘‘Empty vectors’’ panel). Overexpression of FACT together
with H-Ras V12 significantly increased the proportion of actively
growing transformed-like cells, which quickly became predomi-
nant even without passaging (Figure 2A, ‘‘H-RasV12’’ plus
‘‘SSRP1+SPT16’’ panel). Transduction of H-RasV12 into fibro-
blast and epithelial cells leads to the appearance of cells able
to grow in semisolid medium and in vivo in animals. FACT over-
expression significantly increased the proportion of these cells
(Figures S1D, S1E, and 2B), whereas FACT KD almost
completely eliminated them (Figures 2C and 2D). Importantly,
overexpression of FACT alone (without H-Ras V12) was not suffi-
cient to induce MEF or MCF10A cells to grow in semisolid media
(Figures S1D, S1E, and 2B). These data suggest that FACT pro-
motes, but cannot on its own drive, cellular transformation.
To test if FACT is also essential for established transformed
cells, we compared the effects of FACT KDon the growth of pairs
of tumor and nontransformed ‘‘normal’’ cells of the same tissue
(fibroblasts, kidney and mammary epithelia; Figure 2E). It should
be noted that unlike primary normal cells in vitro or in vivo, all
tested established cell lines (transformed and nontransformed)
express both FACT subunits (Figure 2F). Because a parallel
study demonstrated coregulation of SSRP1 and SPT16 levels,
shRNA against either FACT subunit effectively eliminated both
SSRP1 and SPT16 (Safina et al., 2013). We found that FACT
KD suppressed the growth of all tumor cells but had a smaller
or no effect on the growth of nontransformed cells (Figure 2E).
For two out of three cell pairs (kidney and fibroblasts cells),
nontransformed cells surviving shRNA transduction showed
effective FACT KD, whereas corresponding tumor cells did not
(Figure 2F). These data suggested that unlike nontransformed
cells, tumor cells cannot grow in the absence of FACT. This
was subsequently confirmed in the MCF7 (tumor)/MCF10A
(nontumor) cell pair through comparison of cell growth and
FACT expression at different times after transduction of
shSSRP1 or shSPT16 (Figure S2).
Further illustrating that FACT is required for tumor cell growth,
immunofluorescent staining of shSSRP1-transduced cell cul-
tures revealed that the proportion of cells with low SSRP1 levels
decreases with time (Figure 2G). Moreover, tumor cells with low
FACT levels had reduced replication rates (Figures 2H and 2I)
accumulated in G1 (Figure 2H), and some died (Figure 2H, red
arrow, and Figure 2J). Although these data support a role for
FACT in DNA replication, the absence of S phase arrest (which
would be expected if FACT is needed only for replication)
suggests that signaling leading to G1 arrest and/or other
FACT-dependent processes (e.g., transcription) may also be
vital for tumor cells.
Chromatin-Embedded FACT Is Enriched at Genes
Associated with Cancer and Cell Pluripotency
The known activities of FACT suggest that it may promote tumor
growth by altering chromatin in a way that facilitates transcrip-
tion of genes important for transformation. FACT does not affect
general transcription (Figures S3A–S3C) but has been shown to
be required for transcription driven by particular transcriptionfactors (TFs) such as NF-kB (Gasparian et al., 2011), the activity
of which is critical for many types of tumor cells (Gudkov et al.,
2011). To identify other FACT-dependent transcriptional pro-
grams or genes, we used chromatin immunoprecipitation
(ChIP) followed by next-generation sequencing (NGS) to
examine the distribution of chromatin-bound FACT in HT1080
tumor cells, the growth and survival of which require FACT (Fig-
ures 2E–2J). Three independent ChIP experiments were per-
formed on unsynchronized, growing HT1080 with anti-SSRP1
antibodies shown to be highly specific (LC/MS of immunoprecip-
itated complex) and not interfere with either SSRP1/SPT16 asso-
ciation or binding of FACT to chromatin (Figure S4; Gasparian
et al., 2011). As a specificity control for anti-SSRP1 ChIP, we
used cells treated with the small molecule CX (CX-137), which
causes depletion of FACT from sites of active transcription (Gas-
parian et al., 2011).
NGS of DNA fragments that coprecipitated with SSRP1 re-
vealed a nonrandom genomic distribution of SSRP1 in HT1080
cells (Figures 3 and S5). Of SSRP1 peaks, 47% occurred near
protein-coding genes, a distribution that is significant relative
to a random target list (p < 0.0001). FACT distribution in relation
to genome features is shown in Figure 3A and to TSS in Fig-
ure S5B. Gene-associated SSRP1 peaks were much more
similar to broad RNA polymerase II peaks than to sharp peaks
of sequence-specific TFs (Figure S5C). CX treatment substan-
tially reduced association of FACT with genes (Figure 3A), con-
firming our previous findings that CX treatment depletes FACT
from areas of gene transcription (Gasparian et al., 2011). As
expected, SSRP1 bound NF-kB-dependent genes, and this
binding was reduced after CX treatment (Gasparian et al.,
2011; Figure S6). In total, we identified 2,085 genes in HT1080
cells with significant enrichment of SSRP1 over background
(Table S1). For 93%of these genes, SSRP1 binding was reduced
(R2-fold) after CX treatment. To strengthen our gene enrichment
analysis, we selected 267 genes with SSRP1 binding >10-fold
over background (200 kB around the TSS) that were significantly
CX sensitive (Table S1).
Functional annotation of the list of SSRP1-enriched genes was
accomplished by assessing overlap with the Molecular Signa-
ture Database (MSigDB, Broad Institute, Harvard University,
MIT) curated gene lists. We obtained 52 lists with significant
overlap (p < 1.0 3 105; FDR <0.05), which we divided into
several functional categories (Tables 1 and S2): (1) MYC related;
(2) stress induced (by UV, hypoxia, TNF, or genotoxic drugs); (3)
cancer related (changed in cancer versus normal samples or in
high-grade versus low-grade cancers); (4) meiosis and ribosome
related, (5) growth factor induced; (6) associatedwith dedifferen-
tiation; and (7) miscellaneous (including genes associated with
system lupus erythematous [chronic inflammation], genes
involved in the cell cycle, genes bound or upregulated by E2F
TFs, and several other categories). This set of functional attri-
butes suggests that FACT may be important for regulating
expression of genes that stimulate proliferation, inhibit differenti-
ation, and/or control stress responses.
As shown previously for NF-kB, FACT may control expression
of the SSRP1-associated genes through interactions with partic-
ular TFs. To identify such TFs, we compared our list of SSRP1-
enriched genes with (1) a list of genes with promoters containingCell Reports 4, 159–173, July 11, 2013 ª2013 The Authors 161
Figure 2. Transformation and Tumor, but Not Normal, Cell Growth Require FACT Expression
(A and B) Overexpression of FACT increases the efficiency of transformation of MCF10A cells by H-RasV12. (A) Microphotographs of 2D col-
onies 6 days after transduction of MCF10A cells with the indicated constructs. (B) Number of colonies in semisolid medium for MCF10A
cells transduced with the indicated constructs or empty vectors (), the mean of triplicates + SD; *p < 0.05 for comparison to cells transfected with both empty
vectors.
(C and D) KD of SSRP1 suppressesH-RasV12-induced transformation of MCF10A cells. (C) MTT-stained colonies in semisolid medium in triplicate wells grown for
37 days after transduction of MCF10A cells with shRNAs. The darker color of shSSRP1 wells is due to unreducedMTT. (D) Growth of tumors (n = 10) in SCIDmice
(legend continued on next page)
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sequence elements known as TF binding sites using MSigDB
(Table S3), and (2) lists of TF target sequences known from the
literature using GenGo (Thomson Reuters) (Table S4). TFs iden-
tified by both methods are shown in Figure 3C. Most have
well-established associations with cancer or embryonic devel-
opment; importantly, all except one (TP53) promote tumor
growth as oncogenes (MYC, JUN, Ets-family, YY1), inducers of
cell proliferation (SP1, CREB, SRF), suppressors of apoptosis
(NF-kB), or inhibitors of cell differentiation (OCT1, OCT4). More-
over, analysis of associations of SSRP1-enriched genes with
disease states usingGeneGo showed thatmost significant asso-
ciations were with different types of neoplasms (Figure 3B).
In addition, we found that genes for several TFs including
MYC, JUN, JUNB, JUND, FOSL1, and FOSL2 (but not TP53)
were themselves significantly ‘‘SSRP1 enriched’’ (Figure 3D).
Thus, FACT may affect expression of some TFs themselves in
addition to their targets.
FACT Subunits Are Overexpressed in Multiple Types
of Tumors
To evaluate the clinical significance of our in vitro findings, we
compared SSRP1 and SPT16 mRNA levels in human tumor
and normal tissue using publicly available high-content micro-
array data and In Silico Transcriptomics Online-Integrated
gene expression reference database (IST) Online software
(MediSapiens) for transtechnology and transstudy normaliza-
tion. This revealed that SSRP1 mRNA, whereas showing signifi-
cant variability among different samples, was elevated in the
majority of tumors as compared to tissue from patients with no
disease or noncancer-related diseases (Figure 4). Cultured cell
lines included in the analysis had the highest average level of
SSRP1 of any category (Figure 4A), suggesting that in vitro
conditions either induce SSRP1 expression or select cells with
elevated SSRP1.
SPT16 mRNA was also elevated in tumors, but to a lesser
extent than SSRP1 (Figure S7). This difference was consistent
with our finding that SSRP1 mRNA and protein both increased
in the process of HMEC transformation, whereas for SPT16,
only protein (not mRNA) levels increased (Figures 1B and 1C).
This is most likely due to the demonstrated dependence of
SPT16 protein levels on SSRP1 (Safina et al., 2013). Neverthe-
less, as for SSRP1 mRNA, a significant number of tumors with
very high levels of SPT16 mRNA were observed among various
types of cancer.30 days after inoculation of mice with MCF10A cells transduced with the indicate
inoculation; p value (t test) is shown.
(E) Growth of tumor (HT1080, RCC45, MCF7) and nontumor (WI38, NKE, MCF10
triplicates of methylene blue staining (HT1080/Wi38) or colony number (RCC45/
*p < 0.05.
(F) Western blot detection of FACT subunits in the cells described in (E) after pur
(G) FACS analysis of SSRP1 staining in HT1080 cells 120 and 144 hr after transd
(H) Cell-cycle distribution (FACS with DAPI staining) of HT1080 cells 120 hr (left c
latter population separated based on SSRP1 staining as shown in (G).
(I) EDU incorporation indicative of DNA replication 3 days after transduction of c
transduction in the same cells.
(J) Proportion of dead cells detected using Annexin V and propidium iodide stai
indicated shRNAs. *p < 0.05 for comparison to shGFP cells.
See also Figure S2.As a more direct evaluation of FACT expression in a clinical
setting, we performed immunohistochemistry (IHC) staining of
SSRP1 on tissue microarrays (TMAs) containing primary and
metastatic tumors of different types as well as matching normal
tissue from 793 patients (see Experimental Procedures). Tumors
on the TMAs included invasive breast ductal and lobular carci-
noma, non-small-cell lung cancer (NSCLC), renal cell carcinoma
(RCC), and prostatic, pancreatic ductal (PDA), and colorectal
adenocarcinomas. SSRP1 staining was used to assess FACT
levels based on the previously established strong correlation
between SSRP1 and SPT16 protein levels (Garcia et al., 2011).
SSRP1 staining was scored using a semiquantitative system
reflecting both the intensity of staining and the proportion of pos-
itive cells (see Experimental Procedures). On the TMAs, all cells
in normal tissue samples were SSRP1 negative, with the excep-
tion of epithelial cells at the bottom of intestinal crypts (Figures
5A–5C; Garcia et al., 2011). Similarly, whereas tumor samples
were frequently SSRP1 positive (see below), stromal cells pre-
sent in the sample, constituting the tumor microenvironment,
were invariably SSRP1 negative (Figures 5A–5C). The highest
incidences of SSRP1-positive samples were observed in NSCLC
(45%–63%), PDA (59%) and colon adenocarcinoma (50%) (Fig-
ure 5D). In contrast, very few cases of prostatic adenocarcinoma
andRCCwere SSRP1 positive (<10%) (Figure 5D). Therefore, we
deemed the cohort of lung, pancreatic, and colon cancers to be
‘‘high SSRP1 expressors,’’ whereas prostate and kidney cancers
appear to be ‘‘low SSRP1 expressors.’’ Notably, all cancers
categorized as high SSRP1 expressors have a much lower over-
all survival rate as compared to low SSRP1 expressors. In line
with this, invasive ductal carcinoma of the breast, which has an
intermediate survival rate, was found to have an intermediate
incidence of SSRP1-positive/-high samples (18%/13%). In
contrast to the 100% incidence of SSRP1 expression in human
tumor cell lines in vitro, but consistent with ourmRNA expression
data, a certain proportion of all tumor types were observed to
have no SSRP1 staining (Figure 5D).
Correlation of FACT Levels with Clinicopathological
Features of Tumors
Having established that some tumors are SSRP1 and SPT16
positive, whereas others are not, we evaluated whether FACT
subunit expression correlated with any clinicopathological fea-
tures of different types of tumors. Analysis of SSRP1 is described
below; analysis of SPT16 shown in Extended Experimentald shRNAs (bars indicate the mean fold tumor volume at day 30 to day 1 after
A) cells after shRNA transduction/puromycin selection. Bars show the mean of
NKE, MCF7/MCF10A) ± SD, normalized to shGFP data in the same cell type.
omycin selection.
uction with shSSRP1.
olumn) and 144 hr (right) after transduction with shGFP or shSSRP1, with the
ells with the indicated shRNAs. *p < 0.05 for comparison to data with shGFP
ning (double positive) among HT1080 cells 5 days after transduction with the
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Procedures was generally concordant with SSRP1 (Figures S7,
S8, S9, S10, S11, and S12). No correlation between tumor stage
and SSRP1 mRNA or protein level was found in any of the
analyzed tumor types. This suggests that expression of FACT
subunits is an early event in tumorigenesis and does not change
with tumor growth (Table S5; Figures S8, S9, S10, S11, and S12).
However, several cancers (breast, lung, and colon) showed a
correlation between tumor grade and FACT expression, with
significantly higher levels of SSRP1 mRNA and protein in high-
grade, poorly differentiated tumors (Table S5; Figures 6C, 6D,
S8C, S9F, S11D, and S11E).
Among patients with breast cancer, SSRP1mRNA was higher
in all tumor types versus normal breast tissue (Figure 6A) and in
basal versus luminal carcinomas (Figure 6B). SSRP1 protein
expression was more frequent in triple-negative versus hormone
receptor-positive tumors and in ER-negative and Her2-positive
versus ER-positive and Her2-negative tumors (Figure 6D; Table
S5). Similarly,SSRP1mRNAwas higher in NSCLC than in normal
lung, and the highest level was observed in undifferentiated
large-cell carcinomas (Figures S9A and S9C). The same ten-
dency, although not statistically significant, was observed for
SSRP1 protein (Figure S9E). Notably, among different histologi-
cal subtypes of breast cancer and NSCLC, high SSRP1 expres-
sors were generally tumor subtypes with worse prognoses than
low SSRP1 expressors.
Because most cancer-related deaths are due to metastatic
rather than primary disease, we evaluated whether SSRP1
expression is associated with metastatic disease. We found
that patients with breast cancer and with RCC with SSRP1-
positive primary tumors had a higher incidence of metastatic
disease than patients with SSRP1-negative primary tumors (Fig-
ures 6D and S10D). In addition, SSRP1mRNAwas higher among
patients with metastases of lung and prostate cancers than
among patients with no metastasis (Figures S9D and S12A).
Overall, there was a strong correlation of SSRP1 status between
primary and metastatic lesions in all cancers analyzed by IHC
(97%). Therefore, the presence of SSRP1 in primary tumors of
several types (e.g., breast) may be predictive of metastatic
disease.
The data described above suggested that SSRP1 expression
might be associated with tumor aggressiveness. To test this, we
performed a correlation analysis between SSRP1 protein level
and overall survival for all patients as a single cohort regardless
of their tumor classification. To determine whether a particular
degree of SSRP1 overexpression had prognostic value, we
compared the following groups (defined by semiquantitative
score cutoffs; see Experimental Procedures): (1) ‘‘high’’ SSRP1
versus ‘‘low’’ and negative samples, (2) positive SSRP1 versus
weak/negative samples, and (3) SSRP1-negative versus all
positive samples. For all tumor types, the strongest correlationFigure 3. Analysis of Genome-wide Distribution of SSRP1 in Tumor Ce
(A) MACS statistics of the distribution of SSRP1 tags in relation to genomic featu
(B) GeneGo analysis of association of SSRP1-enriched genes with diseases; p v
(C) Families of TFs involved in regulating expression of SSRP1-enriched genes (
(D) Enrichment of SSRP1 binding to TF genes. Data are shown as alignments of S
HT1080 cells left untreated (control, replicates r1–r3) or treated with CX (CX-137
See also Figures S3, S4, S5, and S6 and Tables S1, S2, S3, and S4.between survival and SSRP1 level was obtained if SSRP1-posi-
tive and -negative samples were compared (Figures 5E and
S13A). For all 793 patients, SSRP1 positivity was significantly
associated with worse overall survival (Figure 5E). The same ten-
dency, although not statistically significant, was observed in lung
and colon cancers (Figure S13). In the tumors of patients with
breast cancer, expression of SSRP1 was significant prognostic
markers of poor survival based on univariate analysis (Fig-
ure S13D). The multivariate analysis of SSRP1 and hormone
receptors status in breast cancer did not reveal SSRP1 as an
independent marker with the number of patients we analyzed,
but combination of SSRP1 with estrogen and progesterone
receptors significantly improves the predictive value of both
the established markers (Figures 6E and 6F). In summary, anal-
ysis of clinical samples indicated that SSRP1 is expressed
more frequently and at a higher level in less-differentiated (higher
grade) and more aggressive tumors, including (1) types of solid
tumors with poor prognosis (lung, pancreatic, and colon); (2) his-
tological subtypes of breast cancer and NSCLC with poor prog-
nosis (triple negative, Her2 positive, large undifferentiated lung
carcinoma); (3) metastatic tumors (breast, lung, renal, and pros-
tate cancers); and (4) tumors from patients with low overall
survival.
DISCUSSION
Although we and others previously noted elevated expression of
FACT in tumor cell lines and in ovarian cancer patient samples
(Gasparian et al., 2011; Hudson et al., 2007; Koman et al., 2012),
this study provides a comprehensive analysis of FACT’s value
as a cancer marker and target. First, we found that both FACT
subunits were elevated upon in vitro transformation of
fibroblasts and epithelial cells induced by different agents (Fig-
ures 1 and S1). These data, together with the already-published
observation that FACT is elevated upon Her2/neu-induced
transformation of mammary epithelial cells (Koman et al.,
2012), suggest that FACT upregulation may be a universal event
during in vitro transformation. In epithelial cells, but not fibro-
blasts, the intermediate step of immortalization was accom-
panied by modest FACT elevation (Figure 1A); however, the
most critical increase in both cell types coincided with transfor-
mation and acquisition of malignant properties, such as AIG
and/or in vivo tumor growth (Figures 1A–1C, S1B, and S1C).
Similarly, ectopic FACT expression induced growth in 2D cul-
tures for epithelial cells, but not fibroblasts, while increasing
the proportion of cells able to grow in semisolid medium for
both cell types (Figures 2A–2C, S1D, and S1E). Because the
same oncogene was used to transform both cell types, these
data likely reflect cell-type-specific requirements for FACT
during transformation.lls
res in HT1080 cells untreated or treated with 3 mM CX-137 for 1 hr.
alues are shown, FDR <0.05.
see details in the text and full lists in Tables S1 and S2).
SRP1-bound DNA sequencings from three independent ChIP experiments with
, replicates r1–r3) visualized using IGV.
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Table 1. Curated Gene Lists from MSigDB Significantly
Overlapping with the List of SSRP1-Enriched Genes Organized in
Functional Categories
Functional
Category Gene Set Name p Value
MYC related Dang bound by MYC 0.00 3 100
Dang MYC targets up 0.00 3 100
Benporath MYC targets
with E box
5.58 3 1014
Benporath MYC max
targets
1.96 3 1012
GGGAGGRR V$MAZ Q6 8.47 3 109
LEI MYB targets 9.08 3 109
Stress induced ENK UV response
keratinocyte up
0.00 3 100
Dazard response to UV
NHEK up
1.11 3 1016
Krieg hypoxia not via
knockdown M3A
1.75 3 1010
HU genotoxic damage 24 hr 2.56 3 109
Winter hypoxia metagene 7.04 3 109
Harris hypoxia 1.41 3 108
Phong TNF targets up 2.05 3 108
Dazard UV response
cluster G2
2.25 3 108
Cancer related Wang tumor invasiveness up 0.00 3 100
Grade colon cancer up 1.11 3 1016
Osman bladder cancer DN 3.89 3 1015
CHNG multiple myeloma
hyperploid up
6.55 3 1015
LI amplified in lung cancer 7.78 3 1011
Zucchi metastasis DN 7.31 3 1010
Nutt GBM vs AO glioma DN 9.06 3 1010
Sweet lung cancer kras UP 2.82 3 109
Acevedo liver cancer DN 3.51 3 109
Diaz chronic meylogenous
leukemia DN
4.35 3 108
Meiosis Reactome meiosis 0.00 3 100
Reactome meiotic
recombination
0.00 3 100
Reactome meiotic synapsis 3.15 3 1014
Ribosome Kegg ribosome 0.00 3 100
MIPS ribosome cytoplasmic 0.00 3 100
MIPS 60S ribosomal subunit
cytoplasmic
0.00 3 100
MIPS 40S ribosomal subunit
cytoplasmic
2.22 3 1016
Stimulated by
growth factors
Nagashima EGF signaling up 8.58 3 1013
Amit EGF response 40 hela 1.58 3 1011
Nagashima NRG1
signaling up
6.56 3 1011
Pedersen metastasis by
ERBB2 isoform 1
1.12 3 109
Table 1. Continued
Functional
Category Gene Set Name p Value
Chromatin
organization
Reactome deposition
of new cenpa-containing
nucleosomes at the
centromere
1.11 3 1016
Reactome chromosome
maintenance
3.33 3 1012
Differentiation Benporath SOX2 targets 4.74 3 109
ESC V6.5 up early.V1 DN 7.69 3 107
ESC J1 up early.V1 DN 9.86 3 106
Only lists with p < 0.00 3 106 are shown.
See also Tables S1, S2, S3, and S4.
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demonstrated that FACT was not simply correlated with trans-
formation but functionally required. However, enforced expres-
sion of FACT was not able to substitute for H-RasV12 in driving
malignant transformation. This indicates that FACT-mediated
chromatin changes are not sufficient to cause transformation
but, rather, appear to create conditions that promote or accel-
erate the oncogenic activity of other factors. Therefore, FACT
cannot be categorized as an oncogene or ‘‘driver’’ of malignant
transformation, but at the same time, it is not a ‘‘passenger.’’
We suggest the term ‘‘accelerator’’ or factor thatmakes the func-
tion of a driver more efficient.
FACT remains important even in established tumors, as illus-
trated by our finding that all tested tumor cell lines were sensitive
to FACT KD (Gasparian et al., 2011; Figures 2 and S2). Unlike
normal and immortalized nontransformed cells, tumor cell lines
with reduced levels of FACT could not be expanded (Figures
2F and S2). Selective FACT dependence of tumor, but not
normal, cells indicates that targeting of FACT could be a safe
and effective anticancer strategy.
However, many patient tumor samples are FACT negative,
indicating that FACT is not universally important for tumor trans-
formation in vivo. Most normal tissues in vivo, as well as normal
primary cells in culture, are FACT negative. Passaging of these
cells in vitro results in elevation of FACT levels (unpublished
data), suggesting that for normal cells, either in vitro stress
induces FACT expression, or only cells with elevated FACT
(stem or undifferentiated progenitor cells as shown in Garcia
et al., 2011) can grow in culture. Both of these possibilities are
consistent with our observation that many FACT-controlled
genes are either involved in the maintenance of pluripotent cell
state or induced by different types of cellular stress (Table 1),
and there may be a feedback mechanism between stress and
FACT expression. In line with this hypothesis, all tested cultured
tumor cell lines were FACT positive (Garcia et al., 2011; Gaspar-
ian et al., 2011), whereas many patient tumor samples were
FACT negative. Furthermore, SSRP1 and SPT16 mRNA levels
were consistently higher in cultured cell lines as compared to
practically all tissues in vivo (Figures 4 and S7).
Thus, our data show that normal and tumor cells can be either
FACT positive or negative in vivo, whereas both categories are
FACT positive in vitro (although to different extents). The key
Figure 4. SSRP1 mRNA Expression in Patient Samples and Cultured Cell Lines
(A) Dot plot of normalized SSRP1 mRNA levels (y axis; see details in Experimental Procedures) in all analyzed samples (x axis, n = 20,000) shown in an
anatomically and pathologically ordered fashion (x axis colors correspond to the legend at top of panel). Colored dots are those with an expression level 1 SD
higher than the average expression in all samples of the same type (normal, tumor, nontumor diseased, etc., as shown above panel) or those in which the 90th
percentile of expression wasmore than two times the interquartile range plus the 75th percentile of the same type. However, no anatomy or cancer type is colored
if there were fewer than ten data points per tissue type. Red lines indicate median for each sample category.
(B) Tissue box-whisker plot of SSRP1 expression in samples of nondiseased (healthy) and cancer tissues. All results with at least five samples are shown. Green
boxes indicate nondiseased samples, whereas red boxes indicate cancer(s). Boxes span the 25th–75th percentile of the data with the horizontal line at themedian.
The whiskers extend to 1.5 times the interquartile range from the edges of the box, and any data points beyond this were considered outliers (hollow circles).
See also Figure S7.difference between these cell types is that tumor cells are sensi-
tive to FACT inhibition, whereas normal cells are not (Figures 2
and S2). This was also true in vivo because inhibition of FACT
activity by CXs had antitumor effects in multiple mouse models
at nontoxic concentrations (Gasparian et al., 2011).
To extend the relevance of our findings in cultured cells (see
above) and in CX-treated mice toward patients with cancer, we
investigated FACT expression in a large number of human
normal and tumor tissue samples via (1) analysis of publicly avail-
able microarray-based gene expression data sets, and (2) IHC
staining of TMAs containing an independent set of samples.
The bioinformatics approach first suggested that FACT may
not be a universal cancer marker because not all tumor samples
displayed elevated FACT levels (Figures 4 and S7). Trying to
clarify the difference between tumors with low and high levels
of FACT, we noticed that the most significant association withclinical features was between FACT-positive and -negative
tumors. Thus, whether tumor cells express FACT or not appears
to be more important than the level of expression. Notably, mul-
tiple specific subtypes of tumors had a high incidence of FACT
positivity, and almost universally, these subtypes behaved
more aggressively (overall survival of patients with FACT-posi-
tive tumors was significantly worse than that of patients with
FACT-negative tumors; Figure 5E).
In line with FACT expression in normal mouse and human tis-
sues being limited to stem and undifferentiated progenitor cells,
FACT expression was positively correlated with grade for several
cancer types (Table S5). This suggests that FACT is mostly
expressed in poorly differentiated tumors. We did not observe
this correlation in PDA; however, our PDA sample set did not
include any well-differentiated tumors, only moderately and
poorly differentiated ones (which are aggressive, have poorCell Reports 4, 159–173, July 11, 2013 ª2013 The Authors 167
Figure 5. SSRP1 Protein Expression in Human Tumors Is Associated with Poor Overall Patient Survival
(A–D) Examples of IHC staining with antibodies to SSRP1 containing normal (N) and tumor (T) tissues of lung and colon (A), breast (B), and pancreatic (C) tissues.
(D) Proportion of patients with SSRP1 expression in their tumors (‘‘Positive’’ indices aremore than one, and ‘‘High’’ indices aremore than four; te scoring system is
described in Experimental Procedures) out of all analyzed patients with the same type of cancer.
(E) Patients with SSRP1-negative tumors have better overall survival. Kaplan-Meier survival curves were built using data for all analyzed patients (n = 793). The
p value was calculated using the log rank test.
See also Figure S13 and Table S5.
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Figure 6. SSRP1 mRNA and Protein Expression in Breast Cancer
(A–C) Box-whisker plots of SSRP1 mRNA levels in (A) samples of breast tissue (aCa, adenocarcinoma); (B) breast cancer samples categorized by gene
expression signature; and (C) breast cancer samples of different grades and stages. p Values fromMann-Whitney-Wilcoxon tests between indicated samples are
shown. p Values >0.05 are not shown.
(D) Comparison of the proportion of SSRP1-positive samples (based on IHC staining) among patients within different categories of breast cancer. The p values
from exact Fisher chi-square tests between different categories are shown.
(E and F) Combination of SSRP1 expression with negative ER (E) and PR (F) status is a significant predictor of poor survival in patients with breast cancer. Kaplan-
Meier survival curves for each combination of markers.
See also Figures S8, S9, S10, S11, and S12.
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prognosis, and consistent with our hypothesis, were frequently
FACT positive).
Further supporting the association of FACTwith tumor aggres-
siveness, FACT expression was found to be significantly corre-
lated with metastasis of breast, renal, and prostate cancer.
Importantly, the FACT status (SSRP1 staining on TMA) of the
primary tumor was associated with the development of metasta-
tic disease. This, together with the lack of correlation between
FACT expression and tumor stage or timing, increases the
potential value of FACT as a prognostic marker because FACT
positivity of a primary tumor could be used at a very early stage
to determine the risk for future metastatic disease.
Although all of our data indicate that the SSRP1 and SPT16
subunits of FACT are coordinately expressed in cancer,
SSRP1 is the most promising candidate for a diagnostic/prog-
nostic marker because its upregulation is more obvious on
both the mRNA and protein levels. This likely derives from the
unusual mechanism of SSRP1 and SPT16 coregulation that we
recently described in which the stability of both proteins
depends upon formation of the FACT complex, and stability of
the complex is determined by the presence of SSRP1 mRNA
(Safina et al., 2013). In this way, an increase of SSRP1 mRNA
is sufficient to drive elevation of both SSRP1 and SPT16 pro-
teins. This was confirmed in the in vitro transformation experi-
ments reported here: whereas only SSRP1 (not SPT16) mRNA
was elevated in all transformed cells, protein levels of both
SSRP1 and SPT16 were increased (Figures 1A–1C). This same
trend was noted in many types of tumors: SSRP1 mRNA was
increased much more universally than SPT16 mRNA (Figures
4, 6, S7, S8, S9, S10, S11, and S12). At the same time, we did
observe tumors with significantly increased SPT16 mRNA (Fig-
ure S7). In the future, it will be interesting to analyze whether
these tumors have any selective advantages over those in which
only SSRP1 mRNA is elevated.
The mechanism(s) underlying FACT’s role as an accelerator
of transformation remains to be fully elucidated. However, our
previous demonstration that FACT-assisted NF-kB-dependent
transcription is involved suggested that modulation of transcrip-
tional programs driven by other TFs might also contribute to
FACT’s procancerous effects. Support for this hypothesis was
gained through our ChIP-based exploration of the distribution
of chromatin-bound SSRP1. This confirmed significant and
selective association of FACT with protein-expressing genes
(Figures 3A, 3D, and S5). SSRP1 peak distribution over thewhole
body of genes, with additional enrichments at the start and end
of the gene territory, indicated involvement of FACT in transcrip-
tion initiation, elongation, and possibly termination. The selec-
tivity of FACT in assisting the transcription of some, but not other,
genes was previously demonstrated through comparison of
gene expression profiles in yeast (reviewed in Formosa, 2012),
plant, and mammalian cells following inactivation of FACT (Dur-
oux et al., 2004; Li et al., 2005; Lolas et al., 2010).
The list of SSRP1-enriched genes obtained in our study con-
tains many ‘‘procancer’’ genes, including numerous TF targets
involved in induction of proliferation, inhibition of cell death and
differentiation, maintenance of cell pluripotency, and stress
responses (Tables 1, S2, S3, and S4; Figures 3C and 3D). The
mechanism by which FACT selects these genes is currently170 Cell Reports 4, 159–173, July 11, 2013 ª2013 The Authorsunder study, although FACT has been found among the direct
interactors of several TFs that, based upon SSRP1 binding to
their genes, may require FACT for expression (i.e., MYC, SRF,
and OCT4) (Bunker and Kingston, 1995; Kihara et al., 2008;
Spencer et al., 1999; Pardo et al., 2010; van den Berg et al.,
2010).
We also cannot exclude a nontranscription-related role for
FACT in cancer. FACT is known to be involved in replication,
and replication is clearly reduced upon FACT KD. However,
the availability of cells in vivo and in vitro that can replicate
without FACT suggests that this may not be the only FACT-
dependent process that is vital for tumor cells. Additional
reported functions of FACT that might contribute to its role in
cancer are regulation of DNA damage responses and DNA
repair. However, genes involved in these processes are usually
lost or mutated in cancer (e.g., BRCA, MHS), whereas neither
SPT16 nor SSRP1 displays higher-than-background incidences
of mutations or deletions in any type of cancer (TCGA, cBio por-
tal). SSRP1, but not SPT16, was reported to be required (in
cooperation with many other factors) for proper spindle forma-
tion during mitosis (Zeng et al., 2010). We cannot exclude that
elevation of SSRP1, and concomitantly SPT16, levels may be
due to the increased rate of mitosis in cancer cells; however, it
seems unlikely that an artificial increase in FACT expression
would induce transformation by assisting with spindle formation.
Understanding the mechanism(s) by which FACT promotes
cancer is a major goal of our current work.
In conclusion, the results of this study indicate that FACT is a
promising marker and target for subtypes of cancer character-
ized by high grade and aggressiveness and poor prognosis.
This, together with the absence of FACT expression in most
normal cells/tissues, suggests that pharmacological inhibition
of FACT could be a safe and effective strategy to treat types of
cancer for which there are currently few treatment options.
EXPERIMENTAL PROCEDURES
Reagents
CX-137 (CBLC137) was provided by Cleveland BioLabs.
Cells
HT1080, WI-38, MCF7, and MCF10A cells were obtained from ATCC and
maintained as suggested. RCC45 and NKE-hTERT cells have been described
(Gurova et al., 2004).
HMECs were obtained from Martha Stampfer (Lawrence Berkeley National
Laboratory) and modified and maintained as described by Garbe et al. (2009).
184B5 and 184AA3 were immortalized following exposure to benzo(a)pyrene
(Stampfer and Bartley, 1985; Stampfer et al., 2003); 184Dp16sMY and
240Lp16sMy were immortalized following transduction of c-Myc and shRNAs
against p16; 184FMY2 immortalized via expression of c-Myc. The immortal-
ized BJ fibroblast cell line with tamoxifen-regulated H-Ras V12 was obtained
from Reuven Agami (The Netherlands Cancer Institute). Wild-type and p53-
knockout MEF cells were obtained from 13.5-day pregnant C57/B6 wild-
type or p53/ mice and maintained in DMEM with 10% FBS and antibiotics.
Growth of cells in semisolid media was assessed as described by Yang et al.
(2012). Colonies were counted unstained in ten blindly selected fields of view in
each of three replicate wells using 103 phase-contrast microscopy or stained
with 5 mg/ml MTT (Sigma-Aldrich) and photographed.
Growth of cells in SCID mice was done according to institution ethical com-
mittee-approved animal protocol. Five million shRNA-transduced MCF10A
cells were subcutaneously inoculated into two sites of female 8-week-old
SCID mice (n = 5) in 50%Matrigel/PBS solution. Tumors were measured once
a week using digital caliper, and volume was calculated using the formula
V = length3 width2/2. Tumor growth was calculated as fold increase of tumor
volume between days 1 and 30 after inoculation.
Plasmids, Transfection, and Lentiviral Transduction
pLV-H-RasV12-Bleo or pLV-Bleo lentiviral vectors were kindly provided by
Dr. Andrei Gudkov (Roswell Park Cancer Institute [RPCI]). Human SSRP1
cDNA was cloned into the pLV-CMV-Neo lentiviral vector and verified by
sequencing. SPT16 cDNA was synthesized (Invitrogen; GeneArt AG) using a
sequence optimized for protein expression by DAPCEL and cloned into
the pMLV HygroR lentiviral vector. Mission shRNAs targeting SSRP1
(TRCN0000019270), SPT16 (TRCN0000001260), and GFP (SHC004) were
obtained from Sigma-Aldrich.
siRNAs targeting SSRP1(On-Target plus SMART pool, catalog #L-011783-
00) or SPT16 (On-Target plus SMART pool, catalog #L-009517-00) and
siCONTROL nontargeting siRNA (catalog #D-001210-01) were from Thermo
Scientific Dharmacon. Transfection was performed using Lipofectamine
2000 reagent (Life Technologies). Lentivirus packaging and infection were
conducted as described (Gurova et al., 2004, 2005).
Western blotting, fluorescent-activated cell sorting, and immunofluorescent
staining were done as described (Gasparian et al., 2011; Gurova et al., 2004,
2005). The list of antibodies used can be found in Extended Experimental
Procedures.
Replication and transcription rates in cells were measured using Click-iT
EDU Alexa Fluor 594 HCS Assay and Click-iT RNA Alexa Fluor 488 HCS Assay
kits (Invitrogen). Quantitative RT-PCR was done as described (Safina et al.,
2013).
Patient Samples
Patients included in this study (n = 793) were diagnosed with cancer between
March 1992 and January 2010 at RPCI. The RPCI institutional review board
gave approval for this study. We selected all patients from this time period
with adequate material in the RPCI archive for IHC and with follow-up informa-
tion in the RPCI tumor registry or various RPCI research program databases.
The 793 patients included 143 with invasive ductal carcinoma of the breast,
13 with invasive lobular carcinoma of the breast, 54 with colorectal adenocar-
cinoma, 10 with chromophobe RCC, 235 with clear-cell RCC, 15 with papillary
RCC, 10 with RCC unclassified, 73 with lung adenocarcinoma, 11 with lung
large-cell carcinoma, 42 with lung squamous cell carcinoma, 54 with ductal
adenocarcinoma of the pancreas, and 133 with prostatic adenocarcinoma.
Demographic details and number of patients with representative tumors are
provided in Extended Experimental Procedures and Table S6.
TMAs
SSRP1 protein expression in the clinical cohort was assessed using 16 TMAs
comprising six cancer types collected from patients described above. All RPCI
TMAs are built in a standardized fashion with three 1 mm tissue cores from
formalin-fixed paraffin-embedded donor blocks precisely arrayed into a new
recipient paraffin block, including tumor specimens as well as controls. For
most TMAs, three cores of matching normal tissue were also evaluated. Addi-
tional controls within each TMA consisted of multiple cores of normal tissue
from ten different organs including heart, colon, kidney, adrenal, ovary, myo-
metrium, brain, thyroid, lung, and prostate representing slightly more than
20% of all cores per TMA.
TMA Scoring
TMAs were stained as described (Garcia et al., 2011). Results were recorded
according to the American Society of Clinical Oncology Guideline Recommen-
dations. The neoplastic cells for any given core were scored in a semiquanti-
tative/ordered categorical manner for intensity (range of scores 0–3) and
percentage of cells: 0 (0%), 1 (1%–9%), 2 (10%–49%), 3 (50%–100%) staining.
The results for all cores for one patient in a TMA format were averaged for a
final score. An IHC index (range of scores 0–9) was defined as the product
of the intensity and percentage of cells staining. Cores were excluded from
evaluation due to an absence of tumor cells, or core drop-off. Cases were
also excluded if there was insufficient clinical or outcome data.Statistical Analysis of TMA Staining
The SSRP1 IHC data were dichotomized as described in the TMA Scoring sec-
tion. Fisher’s exact tests were performed to test the association between the
dichotomized SSRP1 expression indices (0 versus all others; <2 versus R2;
%4 versus >4) and other dichotomized categorical variables, such as age
(R60/<60), tumor grade (high/low), stage (early/late), and expression of dis-
ease-specific markers, where available. Chi-square tests were performed to
test for association with categorical variables of more than two levels.
Kaplan-Meier survival analyses with log rank tests (Peto and Peto, 1972) were
employed to assess the correlation between patient survival and SSRP1
expression index. The p values <0.05 were considered significant. Multivariate
survival analysis was conducted using Cox regression. All statistical analyses
were performed using the R statistical programming language (R Team, 2012).
In Silico Analysis of SSRP1 and SPT16 Expression
Analysis of gene expression data from 251 different studies was performed
using the IST Online. Details of this analysis are provided in Extended Exper-
imental Procedures.
Immunoprecipitation of SSRP1/SPT16 Complex
HT1080 cells were lysed in NP40 buffer and rotated at 4C for 15 min. Then,
lysates were centrifuged at 14,0003 g for 15 min, and supernatants were pre-
cleared by rotating them with protein A/G agarose beads at 4C for 1 hr. Cell
lysates at 1 mg/ml concentrations were rotated overnight with anti-SSRP1
(catalog #609702; BioLegend) or control mouse IgG2b (catalog #400302;
BioLegend) at 5 mg/500 ml lysate at 4C. To capture immunocomplexes, Dyna-
beads Protein A (Life Technologies) were added to the lysates according to the
manufacturer’s instructions and then rotated for 1 hr at 4C. Beads were
collected,washed three timeswithcoldPBS,andeither used forLC/MSsample
preparation or boiled in 60 ml of 23 loading buffer for 5 min, after being centri-
fuged briefly to separate the supernatants for SDS-PAGE andwestern blotting.
Sample preparation for LC-MS/MSanalysis, database search, andpeptide and
protein identification are described in Extended Experimental Procedures.
ChIP Sequencing and Analysis
ChIP was performed (three independent experiments) using HT1080 cells left
untreated or treatedwith 3 mMCX-137 for 1 hr with themousemonoclonal anti-
SSRP1 (catalog #609702; BioLegend) and mouse IgG2b antibody (catalog
#400302; BioLegend). ChIP was performed with a kit from Upstate (EMD
Millipore) as outlined by the manufacturer except that Dynabeads Protein A
(Invitrogen) were used instead of Protein A agarose beads. ChIP-isolated
DNA was treated using the standard ChIP-sequencing protocol from Illumina
except that after adaptor ligation, the library was separated on a 2% agarose
gel, and the 150–500 bp region was excised and purified. The resulting ChIP
libraries were single-end sequenced on an Illumina HiSeq 2000 with 50 bp
reads. Each sample was sequenced in a single-flow cell lane and generated
89–190 million reads. The resulting raw sequencing reads were filtered for
quality and aligned to the most recent build of the human genome (hg19)
with BowTie. Peaks were identified, averaged, and normalized against the
background, and input using PeakRanger (Feng et al., 2011). The peak posi-
tions in relation to genome features were calculated using MACS (Zhang
et al., 2008). For this, the data from replicated samples were concatenated
together. The comparison of peaks in untreated and CX-137-treated samples
and peak annotation was performed using an Integrated Genomic Viewer
(Broad Institute, MIH, Harvard University).
ACCESSION NUMBERS
Sequencing data in the form of bed files were deposited in the NCBI database
under accession number GSE45393.
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